WALTHAM, Mass., Nov. 6, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of three posters describing niraparib at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 5-9, 2015, in Boston, Massachusetts. The posters describe the homologous recombination deficiency (HRD) analysis being performed on tumor samples from the ongoing Phase 3 NOVA trial of niraparib in patients with ovarian cancer, in addition to preclinical data demonstrating that niraparib crosses the blood brain barrier in animal models and highlighting potential genetic markers of resistance in animal models of small cell lung cancer.
“We are executing a very comprehensive development program for niraparib, and believe that the emerging profile of this promising candidate warrants expansion to a variety of tumor types, as a monotherapy and in combination with immuno-oncology and other targeted agents,” said Mary Lynne Hedley, Ph.D., President and COO of TESARO. “We are very optimistic about the potential of niraparib for patients with ovarian, breast and other cancers, and we look forward to initiating several new trials in the coming months.”
Presentation Details:
Sunday, November 8, 2015, 12:30 PM to 3:30 PM
Homologous recombination deficiency of high grade serous ovarian tumors from the NOVA Phase III clinical study
Abstract: C53, Location: Session C, Hall C-D
Saturday, November 7, 2015, 12:30 PM to 3:30 PM
The PARP inhibitor, niraparib, crosses the blood brain barrier in rodents and is efficacious in a BRCA2-mutant intracranial tumor model
Abstract: B168, Location: Session B, Hall C-D
Saturday, November 7, 2015, 12:30 PM to 3:30 PM
A mouse avatar tumor maintenance study identified a subset of SCLC patient-derived tumor xenograft models sensitive to the PARP inhibitor niraparib
Abstract: B169, Location: Session B, Hall C-D
About Niraparib
Niraparib is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor. A Phase 1/2 monotherapy study of niraparib has been completed in more than 100 patients with advanced solid tumors. Two Phase 3 trials are currently ongoing to evaluate a single oral dose of niraparib for patients with ovarian cancer and for patients with BRCA-positive breast cancer.
About TESARO
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.
Help employers find you! Check out all the jobs and post your resume.
